By Michael Nevradakis, Ph.D. | The Defender | February 2, 2022 The U.S. Food and Drug Administration (FDA) on Monday granted full approval of Moderna’s Spikevax COVID vaccine for people 18 and older. Similar to the agency’s licensing last year of Pfizer’s Comirnaty vaccine, the approval raised a number of legal questions related to mandates and product availability. Spikevax is a two-dose primary […]
Source